News coverage about Galena Biopharma (NASDAQ:GALE) has been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Galena Biopharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.1967039817191 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Critical Contrast: Galena Biopharma (GALE) vs. Novartis AG (NVS) (americanbankingnews.com)
- Global Therapeutic Vaccines Market Would Reach USD $47.44 Billion by 2022 (digitaljournal.com)
- Keloid Treatment Market to Record Study Growth by 2024 (reports.pr-inside.com)
- Form 4 Galena Biopharma, Inc. For: Oct 10 Filed by: GRAY MARY ANN – StreetInsider.com (streetinsider.com)
- Applying technical analysis concepts on Galena Biopharma, Inc. (GALE) – Wall Street Morning (wallstreetmorning.com)
Galena Biopharma (NASDAQ GALE) traded up 0.000% during midday trading on Tuesday, hitting $0.394. The stock had a trading volume of 49,631 shares. Galena Biopharma has a 1-year low of $0.26 and a 1-year high of $6.98. The company has a 50-day moving average of $0.37 and a 200-day moving average of $0.50. The stock’s market cap is $15.13 million.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.01). During the same quarter in the prior year, the company posted $0.05 EPS. Equities research analysts forecast that Galena Biopharma will post ($0.59) EPS for the current year.
Separately, Maxim Group reissued a “hold” rating on shares of Galena Biopharma in a research note on Wednesday, August 9th.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by BBNS and is the property of of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/galena-biopharma-gale-given-daily-media-sentiment-rating-of-0-14/1699515.html.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with our FREE daily email newsletter.